BIOMODEX Announces New Training Solution for Left Atrial Appendage Closure (LAACS)
04 oct. 2018 07h57 HE
|
BIOMODEX
3D-printed, patient-specific heart marks the company’s move into interventional cardiology BOSTON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- BIOMODEX, an innovative medical technology company using...
ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update
09 août 2018 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018
06 août 2018 16h05 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
31 juil. 2018 08h30 HE
|
ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
23 juil. 2018 08h41 HE
|
InspireMD, Inc.
Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
11 juin 2018 09h53 HE
|
InspireMD, Inc.
Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
29 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Zenosense, Inc.: MIDS Shareholder Update
24 mai 2018 08h43 HE
|
Zenosense, Inc.
VALENCIA, SPAIN, May 24, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and...
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
10 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Cardiometabolic Health Congress (CMHC) Concludes CMHC West 2018
08 mai 2018 10h25 HE
|
Cardiometabolic Health Congress
Boca Raton, May 08, 2018 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress concluded its event CMHC West: Advancing Cardiometabolic Health from East to West on Saturday, May 5th at Wynn Las Vegas....